A cyclic guanosine monophosphate-dependent pathway can regulate net hepatic glucose uptake in vivo

Diabetes

Volumn 61, Issue 10, 2012, Pages 2433-2441

  An, Zhibo ^a   Winnick, Jason J ^a   Moore, Mary C ^a   Farmer, Ben ^a   Smith, Marta ^a   Irimia, Jose M ^a   Roach, Peter J ^a   Cherrington, Alan D ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 BROMO CYCLIC GMP; ADENOSINE PHOSPHATE; GLUCOSE; LIVER ENZYME; PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CATHETER; CONTROLLED STUDY; DOG; ENZYME PHOSPHORYLATION; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORT; HYPERGLYCEMIA; HYPERINSULINEMIA; IN VIVO STUDY; NET HEPATIC GLUCOSE UPTAKE; NONHUMAN; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL;

ANIMALS; BLOOD PRESSURE; CYCLIC AMP; CYCLIC GMP; DOGS; GLUCAGON; GLUCOSE; GLYCOGEN PHOSPHORYLASE; GLYCOGEN SYNTHASE; INSULIN; LIVER; PORTAL VEIN; SIGNAL TRANSDUCTION;

EID: 84866623266     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db11-1816     Document Type: Article

References (39)

1. An Z, DiCostanzo CA, Moore MC, et al. Effects of the nitric oxide donor SIN-1 on net hepatic glucose uptake in the conscious dog. Am J Physiol Endocrinol Metab 2008;294:E300-E306 (Pubitemid 351231455)
2. Denninger JW, Marletta MA. Guanylate cyclase and the. NO/cGMP signaling pathway. Biochim Biophys Acta 1999;1411:334-350 (Pubitemid 29221959)
3. An Z, Winnick JJ, Farmer B, et al. A soluble guanylate cyclase-dependent mechanism is involved in the regulation of net hepatic glucose uptake by nitric oxide in vivo. Diabetes 2010;59:2999-3007
4. Ming Z, Han C, Lautt WW. Nitric oxide inhibits norepinephrine-induced hepatic vascular responses but potentiates hepatic glucose output. Can J Physiol Pharmacol 2000;78:36-44 (Pubitemid 30097348)
5. Zhao Y, Brandish PE, DiValentin M, Schelvis JP, Babcock GT, Marletta MA. Inhibition of soluble guanylate cyclase by ODQ. Biochemistry 2000;39: 10848-10854
6. 1H-[1,2,4] oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) to inhibit soluble guanylyl cyclase in rat ventricular cardiomyocytes. Br J Pharmacol 1999;127:693-700
7. 1H-[1,2,4]oxadiazolo[4,3,-a] quinoxalin-1-one is a nonselective heme protein inhibitor of nitric oxide synthase and other cytochrome P-450 enzymes involved in nitric oxide donor bioactivation. Mol Pharmacol 1999;56:243-253
8. Haramis G, Zhou Z, Pyriochou A, Koutsilieris M, Roussos C, Papapetropoulos A. cGMP-independent anti-tumour actions of the inhibitor of soluble guanylyl cyclase, ODQ, in prostate cancer cell lines. Br J Pharmacol 2008;155:804-813
9. Sekhar KR, Hatchett RJ, Shabb JB, et al. Relaxation of pig coronary arteries by new and potent cGMP analogs that selectively activate type I alpha, compared with type I beta, cGMP-dependent protein kinase. Mol Pharmacol 1992;42:103-108 (Pubitemid 23026133)
10. Myers SR, Biggers DW, Neal DW, Cherrington AD. Intraportal glucose delivery enhances the effects of hepatic glucose load on net hepatic glucose uptake in vivo. J Clin Invest 1991;88:158-167
11. Adkins-Marshall BA, Myers SR, Hendrick GK, et al. Interaction between insulin and glucose-delivery route in regulation of net hepatic glucose uptake in conscious dogs. Diabetes 1990;39:87-95 (Pubitemid 20022890)
12. Hendrick GK, Frizzell RT, Williams PE, Cherrington AD. Effect of hyperglucagonemia on hepatic glycogenolysis and gluconeogenesis after a prolonged fast. Am J Physiol 1990;258:E841-E849 (Pubitemid 20179446)
13. Galassetti P, Shiota M, Zinker BA, Wasserman DH, Cherrington AD. A negative arterial-portal venous glucose gradient decreases skeletal muscle glucose uptake. Am J Physiol 1998;275:E101-E111
14. Morgan CR, Lazarow A. Immunoassay of insulin using a two-antibody system. Proc Soc Exp Biol Med 1962;110:29-32
15. Moore MC, Rossetti L, Pagliassotti MJ, et al. Neural and pancreatic influences on net hepatic glucose uptake and glycogen synthesis. Am J Physiol 1996;271:E215-E222
16. Camacho RC, Donahue EP, James FD, Berglund ED, Wasserman DH. Energy state of the liver during short-term and exhaustive exercise in C57BL/6J mice. Am J Physiol Endocrinol Metab 2006;290:E405-E408 (Pubitemid 43671684)
17. Myers SR, McGuinness OP, Neal DW, Cherrington AD. Intraportal glucose delivery alters the relationship between net hepatic glucose uptake and the insulin concentration. J Clin Invest 1991;87:930-939
18. Satake S, Moore MC, Igawa K, et al. Direct and indirect effects of insulin on glucose uptake and storage by the liver. Diabetes 2002;51:1663-1671 (Pubitemid 34564276)
19. Edgerton DS, Lautz M, Scott M, et al. Insulin's direct effects on the liver dominate the control of hepatic glucose production. J Clin Invest 2006;116: 521-527 (Pubitemid 43228370)
20. Hsieh PS, Moore MC, Neal DW, Cherrington AD. Hepatic glucose uptake rapidly decreases after removal of the portal signal in conscious dogs. Am J Physiol 1998;275:E987-E992
21. Moore MC, Hsieh PS, Flakoll PJ, Neal DW, Cherrington AD. Differential effect of amino acid infusion route on net hepatic glucose uptake in the dog. Am J Physiol 1999;276:E295-E302 (Pubitemid 29100585)
22. Dicostanzo CA, Dardevet DP, Neal DW, et al. Role of the hepatic sympathetic nerves in the regulation of net hepatic glucose uptake and the mediation of the portal glucose signal. Am J Physiol Endocrinol Metab 2006;290:E9-E16
23. Shiota M, Jackson P, Galassetti P, Scott M, Neal DW, Cherrington AD. Combined intraportal infusion of acetylcholine and adrenergic blockers augments net hepatic glucose uptake. Am J Physiol Endocrinol Metab 2000;278:E544-E552 (Pubitemid 30149400)
24. Algara-Suárez P, Espinosa-Tanguma R. 8Br-cGMP mediates relaxation of tracheal smooth muscle through PKA. Biochem Biophys Res Commun 2004;314:597-601 (Pubitemid 38084760)
25. Zhang JN, Hiken J, Davis AE, Lawrence JC Jr. Insulin stimulates dephosphorylation of phosphorylase in rat epitrochlearis muscles. J Biol Chem 1989;264:17513-17523 (Pubitemid 19255589)
26. Lira VA, Soltow QA, Long JH, Betters JL, Sellman JE, Criswell DS. Nitric oxide increases GLUT4 expression and regulates AMPK signaling in skeletal muscle. Am J Physiol Endocrinol Metab 2007;293:E1062-E1068 (Pubitemid 47535838)
27. Zhang J, Xie Z, Dong Y, Wang S, Liu C, Zou MH. Identification of nitric oxide as an endogenous activator of the AMP-activated protein kinase in vascular endothelial cells. J Biol Chem 2008;283:27452-27461
28. Zhang BB, Zhou G, Li C. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab 2009;9:407-416
29. Viollet B, Foretz M, Guigas B, et al. Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol 2006;574:41-53 (Pubitemid 43905795)
30. Foretz M, Ancellin N, Andreelli F, et al. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes 2005;54:1331-1339 (Pubitemid 40586661)
31. Iglesias MA, Ye JM, Frangioudakis G, et al. AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulin-resistant high-fat-fed rats. Diabetes 2002;51:2886-2894
32. Camacho RC, Pencek RR, Lacy DB, James FD, Donahue EP, Wasserman DH. Portal venous 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion overcomes hyperinsulinemic suppression of endogenous glucose output. Diabetes 2005;54:373-382
33. Pencek RR, Shearer J, Camacho RC, et al. 5-Aminoimidazole-4-carboxamide- 1-beta-D-ribofuranoside causes acute hepatic insulin resistance in vivo. Diabetes 2005;54:355-360
34. Vincent MF, Bontemps F, Van den Berghe G. Inhibition of glycolysis by 5-amino-4-imidazolecarboxamide riboside in isolated rat hepatocytes. Biochem J 1992;281:267-272
35. Guigas B, Bertrand L, Taleux N, et al. 5-Aminoimidazole-4-carboxamide-1- beta-D-ribofuranoside and metformin inhibit hepatic glucose phosphorylation by an AMP-activated protein kinase-independent effect on glucokinase translocation. Diabetes 2006;55:865-874 (Pubitemid 44100158)
36. Polekhina G, Gupta A, Michell BJ, et al. AMPK beta subunit targets metabolic stress sensing to glycogen. Curr Biol 2003;13:867-871 (Pubitemid 36573256)
37. Winnick JJ, An Z, Ramnanan CJ, et al. Hepatic glycogen supercompensation activates AMP-activated protein kinase, impairs insulin signaling, and reduces glycogen deposition in the liver. Diabetes 2011;60:398-407
38. Jørgensen SB, Nielsen JN, Birk JB, et al. The alpha2-5′AMP- activated protein kinase is a site 2 glycogen synthase kinase in skeletal muscle and is responsive to glucose loading. Diabetes 2004;53:3074-3081 (Pubitemid 39564481)
39. McBride A, Hardie DG. AMP-activated protein kinase - a sensor of glycogen as well as AMP and ATP? Acta Physiol (Oxf) 2009;196:99-113